Author Correction: Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America

Abstract Circulating recombinant forms (CRFs) represent a substantial proportion of infections in the HIV-1 pandemic. Among 103 CRFs described in the literature, 16 are BF intersubtype recombinants, most of South American origin, of which CRF12_BF is the most widely spread. A BF recombinant cluster identified in Bolivia was suggested to represent a new CRF_BF. Here, we find that this cluster belongs to a larger cluster incorporating 38 viruses collected in 7 countries from 3 continents, 21 of them in Spain, most from Bolivian or Peruvian individuals, and 12 in South America (Bolivia, Argentina, and Peru). It comprises three major subclusters, two associated with Bolivian individuals and one associated with Peruvian individuals. Near full-length genome sequence analyses of five viruses collected in Spain, Bolivia, and Peru revealed coincident BF mosaic structures, with 13 breakpoints, 5 and 6 of which coincided with CRF12_BF and CRF17_BF, respectively, and grouping in a clade closely related to these CRFs and more distantly to CRF38_BF and CRF44_BF, all circulating in South America. These results allow us to identify a new HIV-1 CRF, designated CRF89_BF. Through phylodynamic analyses, CRF89_BF emergence was estimated in Bolivia around 1984. CRF89_BF is the fifth CRF member of the HIV-1 recombinant family related to CRF12_BF

Download Full-text

Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America

Scientific Reports ◽

10.1038/s41598-021-90023-x ◽

2021 ◽

Vol 11 (1) ◽

Author(s):

Elena Delgado ◽

Aurora Fernández-García ◽

Marcos Pérez-Losada ◽

María Moreno-Lorenzo ◽

Ismael Fernández-Miranda ◽

...

Keyword(s):

South America ◽

Phylogenetic Tree ◽

Genome Sequence ◽

Full Length ◽

Recombinant Form ◽

South American ◽

Sequence Analyses ◽

Full Length Genome ◽

South American Origin ◽

Hiv 1

AbstractCirculating recombinant forms (CRFs) contribute substantially to the HIV-1 pandemic. Among 105 CRFs described in the literature, 16 are BF intersubtype recombinants, most of South American origin, of which CRF12_BF is the most widely spread. A BF recombinant cluster identified in Bolivia was suggested to represent a new CRF_BF. Here we find that it belongs to a larger cluster incorporating 39 viruses collected in 7 countries from 3 continents, 22 of them in Spain, most from Bolivian or Peruvian individuals, and 12 in South America (Bolivia, Argentina, and Peru). This BF cluster comprises three major subclusters, two associated with Bolivian and one with Peruvian individuals. Near full-length genome sequence analyses of nine viruses, collected in Spain, Bolivia, and Peru, revealed coincident BF mosaic structures, with 13 breakpoints, 6 and 7 of which coincided with CRF12_BF and CRF17_BF, respectively. In a phylogenetic tree, they grouped in a clade closely related to these CRFs, and more distantly to CRF38_BF and CRF44_BF, all circulating in South America. These results allowed to identify a new HIV-1 CRF, designated CRF89_BF. Through phylodynamic analyses, CRF89_BF emergence was estimated in Bolivia around 1986. CRF89_BF is the fifth CRF member of the HIV-1 recombinant family related to CRF12_BF.

Download Full-text

No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dkab064 ◽

2021 ◽

Author(s):

Basma Abdi ◽

Mouna Chebbi ◽

Marc Wirden ◽

Elisa Teyssou ◽

Sophie Sayon ◽

...

Keyword(s):

Integrase Inhibitor ◽

Routine Care ◽

Biological Data ◽

Recombinant Form ◽

Hiv Integrase ◽

Resistance Mutations ◽

Clinical Routine ◽

Inhibitor Resistance ◽

Hiv 1

Abstract Background Little is known about HIV-1 integrase inhibitor resistance in the CNS. Objectives This study aimed to evaluate integrase inhibitor resistance in CSF, as a marker of the CNS, and compare it with the resistance in plasma. Methods HIV integrase was sequenced both in plasma and CSF for 59 HIV-1 patients. The clinical and biological data were collected from clinical routine care. Results Among the 59 HIV-1 patients, 32 (54.2%) were under antiretroviral (ARV) treatment. The median (IQR) HIV-1 RNA in the plasma of viraemic patients was 5.32 (3.85–5.80) and 3.59 (2.16–4.50) log10 copies/mL versus 4.79 (3.56–5.25) and 3.80 (2.68–4.33) log10 copies/mL in the CSF of ARV-naive and ARV-treated patients, respectively. The patients were mainly infected with non-B subtypes (72.2%) with the most prevalent recombinant form being CRF02_AG (42.4%). The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively. Integrase inhibitor resistance mutations in CSF were similar to those in plasma, except for 1/59 patients. Conclusions This work shows similar integrase inhibitor resistance profiles in the CNS and plasma in a population of HIV-1 viraemic patients.

Download Full-text